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Is the microbe–dementia hypothesis
finally ready for a treatment trial?
Could infections really have something to do with disor-
ders that cause dementia? Several chronic diseases, such
as peptic ulcer, certain cancers, and autoimmune condi-
tions, have established infectious etiologies, either bacte-
rial or viral, but mainstream cognitive disorder research
has not fully considered microbial involvement. Evi-
dence is emerging,1 but the size of the problem—
millions of patients with Alzheimer disease (AD) world-
wide, and increasing—compels searching for clues in the
dark, and not only below the streetlight, especially if
established and safe treatments are available.
Thirty years ago, on the basis of the similar topo-
graphic distribution of AD and herpes encephalitis—
in the temporal and frontal lobes, but also in the
hippocampus—Ball2 speculated about a connection
between dementia and herpesviridae. Thereafter, pro-
fessor Ruth Itzhaki’s3 group in the United Kingdom
has been stubbornly pursuing the idea: they have
repeatedly argued for associations between herpes
simplex virus (HSV) and AD, especially in individuals
with the APOE e4 genotype, known to make one
more vulnerable to AD.
A plethora of studies elegantly link microbial ef-
fects to AD pathology: inflammation, formation of
amyloid plaques, genetic host responses, and so forth.
These pathogenetic mechanisms have been recently
exhaustively reviewed.1 There are also increasing
numbers of epidemiologic reports,1 not only of
HSV, but also of other viruses, especially cytomega-
lovirus, which seems to play a substantial role in
immunosenescence.4
In this issue of Neurology®, Katan et al.5 present
further epidemiologic evidence of an association
between infectious burden and cognitive function in
the multiethnic and population-based Northern Man-
hattan Study. Although the authors primarily used a
composite serologic measure of exposure to both bac-
terial (Chlamydia pneumoniae and Helicobacter pylori)
and viral (cytomegalovirus and HSV-1 and -2) patho-
gens, closer analyses implied that the association was
primarily driven by viral infectious burden. These re-
sults strengthen the idea of an association between
herpesviridae and cognitive decline. However, is the
evidence sufficient to consider new types of prevention
and treatment? Moreover, what causes damage in the
brain is uncertain: a specific pathogen? a collection of
pathogens? interactions among pathogens? In the study
by Katan et al., the infectious burden variable assumed
an additive effect and therefore does not elucidate path-
ogen interactions or the possibility of competitive
antagonism between or among pathogens. Further
research should focus on the roles of combinations of
pathogens in a way that allows for testing of specific
interactions in relation to cognitive outcomes.
Undoubtedly, demonstrating that old-age cognitive
disorders, including AD, are slowly progressing diseases
of viral etiology would revolutionize the dementia
research field (and be Nobel Prize worthy). However,
great challenges remain. Most studies to date have been
cross-sectional and associative, which do not prove cause
and effect. There may be important differences in the
ability of various microbes to provoke amyloid substance
aggregation, the pathognomonic feature of AD. Herpes-
viridae may be a more attractive candidate in this
respect, given their ability to get into the brain and their
potential interactions with APOE.1 However, in case–
control studies of brain tissue, chlamydia and spiro-
chetes actually seemed more robustly associated with
AD than herpesviridae.1 Furthermore, during the
1990s C pneumoniae infection was enthusiastically
greeted as a treatable, microbial cause of coronary artery
disease. Failures in large antibiotic trials tempered the
enthusiasm, and most now consider C pneumoniae
infection possibly important, but only a single factor
contributing to the development of atherosclerosis.6
As always in evidence-based medicine, a randomized
controlled treatment trial would provide final proof.
Interesting findings are emerging from schizophrenia
research. Although valacyclovir treatment did not allevi-
ate schizophrenia symptoms in patients seropositive for
cytomegalovirus,7 a new study seems more promising.
In a small test-of-concept study in individuals with
schizophrenia, a group from Pittsburgh and Harvard
demonstrated a favorable effect of valacyclovir 3 g on
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cognitive domains related to executive function.8 This
finding fits well with unpublished analyses of the edi-
torialists, suggesting that viral infections would be asso-
ciated specifically with those cognitive domains related
to executive function (Aiello and Strandberg, personal
communication, 2013).
But even after these promising results, several
more challenges remain. The mean age in the schiz-
ophrenia trial was 29 years, and the patients were
without significant comorbidity.8 In contrast, cog-
nitive disorders and dementia in old age are more or
less a geriatric syndrome9 with multiple contribut-
ing factors. According to the current state of knowl-
edge, an ideal trial to prove the microbe–dementia
connection would involve not only antiviral but also
antibacterial (e.g., spirochete or chlamydia) and
anti-inflammatory therapy. The trial should be tar-
geted to seropositive individuals possibly with the
APOE e4 genotype and possibly with signs of
inflammation (such as elevated C-reactive pro-
tein).10 Comorbid factors in older patients or the
advanced nature of the dementia might overwhelm
any effect of the intervention.
One has to start somewhere. A first step might be
a randomized controlled trial in patients with AD
using valacyclovir with an adequate dose (possibly
3 g) and duration (6 months or longer) to cover re-
activations of herpesviridae and with careful selec-
tion of sensitive study endpoints (such as the
Alzheimer Disease Assessment Scale–cognitive sub-
scale). Currently, no antimicrobial studies in AD
can be found in trial registries. Such a study is nev-
ertheless worth doing, and the editorialists hope that
the study by Katan et al.,5 along with earlier pioneer-
ing work by other groups that have examined spe-
cific infectious etiologies of cognition and AD, will
stimulate this endeavor.
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